← Back to Search

Tyrosine Kinase Inhibitor

1 for Thrombocytopenic Purpura

Phase 2
Waitlist Available
Research Sponsored by Rigel Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).

Eligible Conditions
  • Thrombocytopenic Purpura

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Month 12
Platelet Count measurement
Summary of Patients Whose Platelet Count Increased by at Least 20,000/mm3 From Baseline to a Total of 30,000/mm3 or More - Week 12
+3 more

Side effects data

From 2010 Phase 2 trial • 18 Patients • NCT00706342
72%
ECCHYMOSIS
72%
Blood glucose increased
72%
Blood pressure increased
67%
DIARRHOEA
67%
PETECHIAE
61%
Blood glucose decreased
61%
Aspartate aminotransferase increased
50%
EPISTAXIS
44%
Blood alkaline phosphatase increased
44%
HEADACHE
39%
Alanine aminotransferase increased
39%
NAUSEA
39%
FATIGUE
33%
RASH
33%
Blood lactate dehydrogenase increased
28%
COUGH
28%
NASOPHARYNGITIS
28%
PYREXIA
28%
OROPHARYNGEAL PAIN
28%
Blood cholesterol increased
28%
Protein total decreased
28%
GINGIVAL BLEEDING
28%
STOMATITIS
28%
VOMITING
22%
OEDEMA PERIPHERAL
22%
MUSCLE SPASMS
22%
ARTHRALGIA
22%
BLOOD BLISTER
22%
CONTUSION
17%
NASAL CONGESTION
17%
HYPERTENSION
17%
RHINORRHOEA
17%
PAIN
17%
PAIN IN EXTREMITY
17%
MUSCULOSKELETAL STIFFNESS
17%
DYSPNOEA
17%
BLOOD UREA INCREASED
17%
HEART RATE INCREASED
17%
ORAL PAIN
17%
RECTAL HAEMORRHAGE
17%
BLOOD BILIRUBIN DECREASED
17%
BLOOD BILIRUBIN INCREASED
17%
BLOOD CALCIUM DECREASED
17%
BLOOD POTASSIUM DECREASED
17%
HAEMORRHOIDS
17%
DIZZINESS
17%
SOMNOLENCE
11%
BACK PAIN
11%
CHEST PAIN
11%
EYE HAEMORRHAGE
11%
UPPER RESPIRATORY TRACT INFECTION
11%
GLOBULINS INCREASED
11%
PALPITATIONS
11%
SKIN HAEMORRHAGE
11%
MOUTH HAEMORRHAGE
11%
HERPES ZOSTER
11%
BLOOD CREATININE INCREASED
11%
URTICARIA
11%
ABDOMINAL PAIN
11%
INFLUENZA
11%
Diarrhea
11%
WEIGHT INCREASED
11%
BLOOD SODIUM DECREASED
11%
ABDOMINAL PAIN UPPER
11%
BLOOD MAGNESIUM DECREASED
11%
BLOOD CHLORIDE DECREASED
11%
EAR PAIN
11%
BLOOD CALCIUM INCREASED
11%
Nausea
11%
GOUT
11%
ANION GAP INCREASED
11%
BILIRUBIN CONJUGATED
11%
PRURITUS
11%
CONSTIPATION
11%
Vomiting
11%
HAEMORRHAGE
11%
THROMBOSIS
11%
VISION BLURRED
6%
POLLAKIURIA
6%
INCREASED TENDENCY TO BRUISE
6%
HYPERSENSITIVITY
6%
AUTOIMMUNE THYROIDITIS
6%
BREAST PAIN
6%
RASH PAPULAR
6%
LYMPHADENOPATHY
6%
CATHETER SITE INFLAMMATION
6%
HYPERLIPIDAEMIA
6%
CARDIAC FAILURE CONGESTIVE
6%
GASTROENTERITIS
6%
Dizziness
6%
BLOOD PHOSPHORUS INCREASED
6%
INFLUENZA LIKE ILLNESS
6%
PURPURA
6%
MEDICAL DEVICE COMPLICATION
6%
OSTEOMYELITIS
6%
URINARY TRACT INFECTION
6%
MUSCULOSKELETAL PAIN
6%
NECK PAIN
6%
DEPRESSION
6%
BRONCHITIS
6%
LOWER RESPIRATORY TRACT INFECTION
6%
DEAFNESS
6%
SKIN LESION
6%
IRON DEFICIENCY
6%
DEEP VEIN THROMBOSIS
6%
DYSPNOEA EXERTIONAL
6%
URINE ABNORMALITY
6%
BREAST ABSCESS
6%
ABORTION SPONTANEOUS
6%
TOOTH INFECTION
6%
PNEUMONIA
6%
ABDOMINAL PAIN LOWER
6%
HAEMANGIOMA
6%
FACIAL PAIN
6%
ATRIAL FIBRILLATION
6%
VITAMIN D DEFICIENCY
6%
ERYTHEMA
6%
BENIGN GASTROINTESTINAL NEOPLASM
6%
DRY SKIN
6%
SKIN DISCOLOURATION
6%
MUCOSAL HAEMORRHAGE
6%
Abortion spontaneous
6%
BLOOD UREA DECREASED
6%
BLOOD PHOSPHORUS DECREASED
6%
Dehydration
6%
Deep vein thrombosis
6%
BLOOD CREATININE DECREASED
6%
BLOOD BILIRUBIN UNCONJUGATED INCREASED
6%
BLOOD MAGNESIUM INCREASED
6%
ANXIETY
6%
RASH PRURITIC
6%
ARTHRITIS
6%
HYPERKALAEMIA
6%
AXILLARY PAIN
6%
LOCAL SWELLING
6%
INFLAMMATION
6%
LEFT VENTRICULAR DYSFUNCTION
6%
RESPIRATORY TRACT CONGESTION
6%
SNEEZING
6%
DYSURIA
6%
Mouth hemorrhage
6%
Rectal hemorrhage
6%
Cardiac failure congestive
6%
Palpitations
6%
Pneumonia
6%
SKIN EXFOLIATION
6%
CATARACT
6%
Gastrointestinal hemorrhage
6%
Gingival bleeding
6%
Urinary tract infection
6%
Anoxic encephalopathy
6%
Petechiae
6%
BILIRUBIN CONJUGATED INCREASED
6%
BLOOD ALBUMIN DECREASED
6%
BLOOD POTASSIUM INCREASED
6%
BLOOD SODIUM INCREASED
6%
DIVERTICULUM
6%
DYSPEPSIA
6%
FAECAL INCONTINENCE
6%
FAECES DISCOLOURED
6%
FREQUENT BOWEL MOVEMENTS
6%
GASTROINTESTINAL HAEMORRHAGE
6%
GASTROOESOPHAGEAL REFLUX DISEASE
6%
HAEMATOCHEZIA
6%
TONGUE BLISTERING
6%
TONGUE DISORDER
6%
POSTNASAL DRIP
6%
DECREASED APPETITE
6%
DEHYDRATION
6%
HOT FLUSH
6%
VENOUS INSUFFICIENCY
6%
SCRATCH
6%
DRY EYE
6%
EYE PAIN
6%
OCULAR HYPERAEMIA
6%
EAR HAEMORRHAGE
6%
VERTIGO
6%
PROSTATITIS
6%
VAGINAL HAEMORRHAGE
6%
HYPOACUSIS
6%
GASTRITIS
6%
ANOXIC ENCEPHALOPATHY
6%
MIGRAINE
6%
MIGRAINE WITH AURA
6%
SINUSITIS
6%
TOOTH ABSCESS
100%
80%
60%
40%
20%
0%
Study treatment Arm
R788 PO

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fostamatinib
FDA approved

Find a Location

Who is running the clinical trial?

Rigel PharmaceuticalsLead Sponsor
31 Previous Clinical Trials
3,830 Total Patients Enrolled
Jeffrey Skolnik, MDStudy DirectorAstraZeneca
12 Previous Clinical Trials
676 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
2007. "Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00706342.
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top